Pharsight

Apgdi patents expiration

1. Myrbetriq patents expiration

MYRBETRIQ's oppositions filed in EPO
MYRBETRIQ Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6346532 APGDI Amide derivatives or salts thereof
Mar, 2022

(1 year, 6 months ago)

US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(a month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6346532

(Pediatric)

APGDI Amide derivatives or salts thereof
Sep, 2022

(1 year, 3 days ago)

USRE44872 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(a month from now)

US8835474 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Nov, 2023

(a month from now)

US7982049 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(a month from now)

USRE44872

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(7 months from now)

US8835474

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
May, 2024

(7 months from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(7 months from now)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(7 months from now)

US8772315 APGDI Pharmaceutical composition for treating overactive bladder
Oct, 2028

(5 years from now)

US8772315

(Pediatric)

APGDI Pharmaceutical composition for treating overactive bladder
Apr, 2029

(5 years from now)

US10842780 APGDI Pharmaceutical composition for modified release
Sep, 2029

(5 years from now)

US11707451 APGDI Pharmaceutical composition for modified release
Sep, 2029

(5 years from now)

US11707451

(Pediatric)

APGDI Pharmaceutical composition for modified release
Mar, 2030

(6 years from now)

US10842780

(Pediatric)

APGDI Pharmaceutical composition for modified release
Mar, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 28 June, 2012

Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Use in combination with the muscarinic antagonist solifenacin succinate for th...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage

MYRBETRIQ family patents

Family Patents

2. Myrbetriq Granules patents expiration

MYRBETRIQ GRANULES Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6346532 APGDI Amide derivatives or salts thereof
Mar, 2022

(1 year, 6 months ago)

US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(a month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6346532

(Pediatric)

APGDI Amide derivatives or salts thereof
Sep, 2022

(1 year, 3 days ago)

US7982049 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(a month from now)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(7 months from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative
May, 2024

(7 months from now)

US10058536 APGDI Pharmaceutical composition containing mirabegron
Mar, 2036

(12 years from now)

US10058536

(Pediatric)

APGDI Pharmaceutical composition containing mirabegron
Oct, 2036

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 25 March, 2021

Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

MYRBETRIQ GRANULES family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic